Equity Details
Price & Market Data
Price: $32.00
Daily Change: +$2.05 / 6.41%
Daily Range: $29.40 - $32.00
Market Cap: $2,201,402,624
Daily Volume: 321,670
Performance Metrics
1 Week: 4.10%
1 Month: 12.09%
3 Months: 13.72%
6 Months: 44.74%
1 Year: 85.90%
YTD: 12.61%
About Pharvaris N.V. (PHVS)
Explore Pharvaris N.V. (PHVS)'s performance at a glance. Current price: 32.00, daily change: +$2.05 / 6.41%. Market cap: 2,201,402,624. Focus on its YTD and 3-month performance.
Company Details
Employees: 129
Sector: Health technology
Industry: Biotechnology
Country: Netherlands
Details
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.